Moderna stock soars after report of potential buyout talks

Investing.com -- Moderna (NASDAQ: MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about "a deal of significant scope," which could include a potential acquisition.

According to the report, which cited a person familiar with the discussions, the nature of the potential agreement remains unclear, with both a buyout and a large partnership being considered as options.

The Cambridge, Massachusetts-based biotech company has been seeking to diversify beyond its COVID-19 vaccine business, which has seen declining demand as the pandemic has waned. Moderna’s shares have fallen more than 40% over the past year prior to today’s jump.

Bloomberg Intelligence analysts Sam Fazeli and Max Nisenwrit expressed skepticism about a full takeover, noting that "a full takeover is unlikely, given that the company’s key non-vaccine asset (mRNA-4157) is already partnered with Merck." The analysts suggested that finding a partner for its vaccine business or emerging cancer portfolio is more likely and "would help alleviate the company’s cash burn."

The company has not officially commented on the reported discussions.

You May Also Be Interested In

• Stripe’s OpenRouter deal signals a new race to control AI economics
• Wolfe Research sees CNH stock flat 2027 outlook on commodity prices
• Active options: MRNA AMD AVGO PLTR GOOGL NFLX PFE SOFI NBIS COIN